PTC Therapeutics Call to Review Topline Results from Duchenne Study

  PTC Therapeutics, Inc.  (NASDAQ: PTCT) will host a conference call Tuesday, June 21^st at 8:00 a.m. E.T. to review topline results from Study 041 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy. The call will be accompanied by a slide presentation which can be accessed through our online webcast.

The webinar can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the webinar and providing the passcode 7033198. A live, listen-only webcast can be accessed on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The accompanying slide presentation will be posted on the investor relations section of the PTC website. A webcast replay will be available approximately two hours after completion of the webinar and will be archived for 30 days following the webinar.

https://www.biospace.com/article/releases/ptc-therapeutics-to-host-call-to-review-topline-results-from-study-041-for-translarna-ataluren-in-nonsense-mutation-duchenne-muscular-dystrophy/